Long
Risk vs. Reward on 1-year investment here
Gann analysis. getting close to major phycological breakout area. Risk captured in red and Reward captured in green. 2021 PT of $12-20.
Fundamental snapshot:
Many catalysts ahead for VBI vaccines. HBV therapeutic is said to be a potential blockbuster, with sales in the BILLIONS. Data from Brii high dose cohort expected Q1 2021 (current quarter), also Covid program could mark major milestone for the company as it is considered a great use case for their eVLP technology. Furthermore, the company received over $30 mill from CEPI for development of a Covid vaccine that worked for S. Africa variant know as VBI-2905 today, 3/10/2021 and it now shows on the company website HERE that VBIV has been working a suite of multivalent coronavirus vaccines coming. Note, multivalent is new and pan-corona virus candidate still expected to begin ph.1/2 later in 2021.
Very exciting times to be in VBIV!
Disclosure: I am long vbiv and not a financial advisor. this information is strictly educational and is not intended to be considered financial advice.
Fundamental snapshot:
Many catalysts ahead for VBI vaccines. HBV therapeutic is said to be a potential blockbuster, with sales in the BILLIONS. Data from Brii high dose cohort expected Q1 2021 (current quarter), also Covid program could mark major milestone for the company as it is considered a great use case for their eVLP technology. Furthermore, the company received over $30 mill from CEPI for development of a Covid vaccine that worked for S. Africa variant know as VBI-2905 today, 3/10/2021 and it now shows on the company website HERE that VBIV has been working a suite of multivalent coronavirus vaccines coming. Note, multivalent is new and pan-corona virus candidate still expected to begin ph.1/2 later in 2021.
Very exciting times to be in VBIV!
Disclosure: I am long vbiv and not a financial advisor. this information is strictly educational and is not intended to be considered financial advice.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.